Stereotaxis receives FDA clearance for MAGiC Sweep™, a robotically navigated electrophysiology mapping catheter for arrhythmia treatment.
Quiver AI Summary
Stereotaxis has received FDA 510(k) clearance for its MAGiC Sweep™ catheter, the first robotically navigated high-density electrophysiology mapping catheter designed to enhance the diagnosis and treatment of complex arrhythmias. This innovative device features 20 electrodes for efficient electroanatomical mapping, facilitating precise navigation in hard-to-reach areas of the heart while prioritizing patient safety with its atraumatic design. The MAGiC Sweep promises to improve workflow in robotic procedures and is seen as a significant advancement in the field of electrophysiology, with potential to enhance cardiac ablation procedures. Stereotaxis' CEO, David Fischel, emphasized that this clearance marks a pivotal moment for the company as it moves forward with a portfolio of robotically-navigated interventional devices, reflecting their commitment to advancing robotics in medical interventions.
Potential Positives
- Stereotaxis received FDA 510(k) clearance for the MAGiC Sweep™ catheter, marking a significant regulatory milestone for the company.
- The MAGiC Sweep catheter is the first robotically navigated high-density electrophysiology mapping catheter, showcasing Stereotaxis's innovation in the field.
- This advancement is expected to enhance the safety and effectiveness of cardiac ablation procedures, potentially expanding the company's market share in electrophysiology.
- The clearance is a part of Stereotaxis's broader innovation strategy to advance multiple robotically-steered interventional devices, indicating future growth potential for the company.
Potential Negatives
- The press release highlights that the MAGiC Sweep is the company's first FDA clearance for an interventional catheter in nearly 20 years, suggesting a long gap in innovation or product development before this release.
- The forward-looking statements section indicates potential risks related to market acceptance, competitive factors, and expense management that could adversely affect future performance.
- The company acknowledges dependence on third-party vendors and the impact of external factors, such as healthcare policy changes and global economic conditions, which may undermine its operational stability and growth prospects.
FAQ
What is the MAGiC Sweep™ catheter?
The MAGiC Sweep™ catheter is the first robotically navigated high-density electrophysiology mapping catheter, enhancing arrhythmia diagnosis and treatment.
What benefits does MAGiC Sweep offer for cardiac procedures?
MAGiC Sweep facilitates efficient mapping, extended reach, precision navigation, and improved patient safety during cardiac ablation procedures.
Who developed the MAGiC Sweep catheter?
The MAGiC Sweep catheter was developed by Stereotaxis, a leader in surgical robotics for minimally invasive endovascular interventions.
When did MAGiC Sweep receive FDA clearance?
MAGiC Sweep received FDA 510(k) clearance on July 28, 2025, marking a significant milestone for Stereotaxis.
How does MAGiC Sweep improve electrophysiology mapping?
MAGiC Sweep provides anatomically accurate maps, utilizes 20 electrodes for detailed mapping, and supports efficient robotic procedural workflows.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$STXS Insider Trading Activity
$STXS insiders have traded $STXS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $STXS stock by insiders over the last 6 months:
- PAUL J ISAAC has made 3 purchases buying 62,788 shares for an estimated $113,616 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$STXS Hedge Fund Activity
We have seen 41 institutional investors add shares of $STXS stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REDMILE GROUP, LLC removed 1,799,465 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,167,058
- ESSEX INVESTMENT MANAGEMENT CO LLC added 343,130 shares (+28.3%) to their portfolio in Q1 2025, for an estimated $603,908
- RENAISSANCE TECHNOLOGIES LLC removed 284,091 shares (-69.9%) from their portfolio in Q1 2025, for an estimated $500,000
- WARBERG ASSET MANAGEMENT LLC added 275,784 shares (+476.8%) to their portfolio in Q1 2025, for an estimated $485,379
- LAGODA INVESTMENT MANAGEMENT, L.P. added 254,315 shares (+6.2%) to their portfolio in Q1 2025, for an estimated $447,594
- TRAYNOR CAPITAL MANAGEMENT, INC. removed 160,509 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $282,495
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 142,402 shares (+471.1%) to their portfolio in Q1 2025, for an estimated $250,627
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its groundbreaking MAGiC Sweep™ catheter. MAGiC Sweep is the world’s first robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.
High density mapping has transformed the EP field, enhancing cardiac ablation procedures by enabling more efficient, detailed and precise identification of arrhythmia origin. The combination of high-density mapping with robotics is designed to offer multiple improvements:
- Efficient High-Density Mapping: Equipped with 20 electrodes, MAGiC Sweep facilitates rapid and detailed electroanatomical mapping of the heart chambers.
- Extended Reach & Precision: Seamless integration with Stereotaxis’ Robotic Systems enables precise navigation of the catheter to otherwise difficult to reach areas of the heart.
- Atraumatic Design: The catheter's design prioritizes patient safety with an atraumatic shaft.
- Anatomical Accuracy: The catheter supports more anatomically accurate maps by avoiding the distension caused by rigid catheters.
-
Efficient Workflow: MAGiC Sweep enables improved robotic procedural workflow, particularly as Stereotaxis advances algorithms that support automated mapping with MAGiC Sweep.
"The development of the first ever robotically navigated high-density mapping catheter is a major milestone for the EP field," said Dr. Roderick Tung, Chief of Cardiology and Director of Cardiovascular Clinical Research at The University of Arizona College of Medicine - Phoenix. "Mapping with multi-electrode catheters has taught us so much in both mechanism and therapy for both atrial and ventricular arrhythmias. Remaining limited to only point-by-point mapping has held back the adoption of robotic navigation, as we have become accustomed to seeing human arrhythmias in exquisitely high resolution. We look forward to the positive impact we expect MAGiC Sweep to have on our patients and new possibilities in the field."
"The ability to combine high-density mapping with robotics is an exciting long-awaited milestone for the community of robotic electrophysiologists and the broader EP field," said Dr. Daniel Cooper, Professor of Medicine and Director of Electrophysiology Lab at Washington University. "By helping us efficiently create more accurate and detailed maps of complex arrhythmia, robotic high-density mapping with MAGiC Sweep supports our efforts to provide the most effective and safe ablation procedures for our patients."
"FDA clearance of MAGiC Sweep marks a pivotal moment for Stereotaxis as we advance a broad portfolio of differentiated robotically-navigated catheters. MAGiC Sweep is Stereotaxis’ first FDA clearance for an interventional catheter in nearly 20 years, but is only the first of multiple robotically-steered interventional devices being advanced as part of our comprehensive innovation strategy," said David Fischel, Stereotaxis Chairman and CEO. "This catheter reflects our commitment to significant innovations that advance robotics in electrophysiology and across endovascular interventions."
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit
www.stereotaxis.com
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.